PMID- 24899791
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140606
LR  - 20211021
IS  - 1177-2719 (Print)
IS  - 1177-2719 (Electronic)
IS  - 1177-2719 (Linking)
VI  - 9
DP  - 2014
TI  - HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese 
      Rheumatoid Arthritis Patients.
PG  - 23-8
LID - 10.4137/BMI.S13654 [doi]
AB  - BACKGROUND: Drug-induced proteinuria can occur in rheumatoid arthritis (RA) 
      patients treated with d-penicillamine, gold salts, or bucillamine (Buc), and 
      represents a drug hypersensitivity reaction. Striking associations of human 
      leukocyte antigen (HLA) alleles with adverse reactions have recently been 
      reported for many drugs. METHODS: We investigated the association of HLA class II 
      with Buc-induced proteinuria (BI-Pro) in 485 Japanese RA patients treated with 
      Buc, of whom 25 had developed BI-Pro. RESULTS AND CONCLUSION: This preliminary 
      study showed a highly significant association of DRB1*08:02 with BI-Pro (P = 1.09 
      x 10(-6), corrected P [Pc] = 1.96 x 10(-5), odds ratio [OR] 25.17, 95% confidence 
      interval [CI] 7.98-79.38). DQB1*04:02 was also significantly associated with 
      increased risk of BI-Pro (P = 2.44 x 10(-5), Pc = 2.69 x 10(-4), OR 10.35, 95%CI 
      3.99-26.83). These findings provide useful information for promoting personalized 
      medicine for RA.
FAU - Furukawa, Hiroshi
AU  - Furukawa H
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Oka, Shomi
AU  - Oka S
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Shimada, Kota
AU  - Shimada K
AD  - Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Musashidai, 
      Fuchu, Japan. ; Department of Rheumatology, Sagamihara Hospital, National 
      Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Sugii, Shoji
AU  - Sugii S
AD  - Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Musashidai, 
      Fuchu, Japan.
FAU - Hashimoto, Atsushi
AU  - Hashimoto A
AD  - Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, 
      Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Komiya, Akiko
AU  - Komiya A
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Fukui, Naoshi
AU  - Fukui N
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
FAU - Miyashita, Taiichiro
AU  - Miyashita T
AD  - Nagasaki Medical Center, National Hospital Organization, Kubara, Omura, Japan.
FAU - Migita, Kiyoshi
AU  - Migita K
AD  - Nagasaki Medical Center, National Hospital Organization, Kubara, Omura, Japan.
FAU - Suda, Akiko
AU  - Suda A
AD  - Department of Rheumatology, Yokohama Minami Kyosai Hospital, Rokuura Higashi, 
      Kanazawa-ku, Yokohama, Japan.
FAU - Nagaoka, Shouhei
AU  - Nagaoka S
AD  - Department of Rheumatology, Yokohama Minami Kyosai Hospital, Rokuura Higashi, 
      Kanazawa-ku, Yokohama, Japan.
FAU - Tsuchiya, Naoyuki
AU  - Tsuchiya N
AD  - Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of 
      Tsukuba, Tennodai, Tsukuba, Japan.
FAU - Tohma, Shigeto
AU  - Tohma S
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sakuradai, Minami-ku, Sagamihara, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140519
PL  - United States
TA  - Biomark Insights
JT  - Biomarker insights
JID - 101288638
PMC - PMC4038630
OTO - NOTNLM
OT  - HLA-DRB1*08:02
OT  - bucillamine
OT  - disease-modifying anti-rheumatic drugs
OT  - drug-induced proteinuria
OT  - rheumatoid arthritis
EDAT- 2014/06/06 06:00
MHDA- 2014/06/06 06:01
PMCR- 2014/05/19
CRDT- 2014/06/06 06:00
PHST- 2013/11/14 00:00 [received]
PHST- 2014/01/23 00:00 [revised]
PHST- 2014/01/22 00:00 [accepted]
PHST- 2014/06/06 06:00 [entrez]
PHST- 2014/06/06 06:00 [pubmed]
PHST- 2014/06/06 06:01 [medline]
PHST- 2014/05/19 00:00 [pmc-release]
AID - bmi-9-2014-023 [pii]
AID - 10.4137/BMI.S13654 [doi]
PST - epublish
SO  - Biomark Insights. 2014 May 19;9:23-8. doi: 10.4137/BMI.S13654. eCollection 2014.